LGM
KMTS

Lykos Global Management’s Kestra Medical Technologies KMTS Stock Holding History

Lykos Global Management’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,000
Closed -$663K – 9
2025
Q4 		$663K Buy
+25,000
New +$644K 0.47% 23

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Lykos Global Management's KMTS Position: Q1 2026 in Review

Lykos Global Management sold out of Kestra Medical Technologies (KMTS) in Q1 2026, closing a stake of 25,000 shares — an estimated $663K sold.

Lykos Global Management first reported a position in KMTS in Q4 2025 and held it in 1 quarter. The position peaked at $663K in Q4 2025. 103 funds tracked by Wall St. Rank hold KMTS as of Q1 2026.

  • Lykos Global Management reported no remaining Kestra Medical Technologies position as of Q1 2026 after selling out during the quarter.
  • Lykos Global Management sold 25,000 Kestra Medical Technologies shares in Q1 2026, an estimated $663K.
  • Lykos Global Management first reported a position in Kestra Medical Technologies in Q4 2025 and held it in 1 quarter.
  • Lykos Global Management's Kestra Medical Technologies position peaked at $663K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q1 2026.

Based on Lykos Global Management's 13F filing for Q1 2026, filed 15 May 2026.